HK1072731A1 - Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives - Google Patents

Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives

Info

Publication number
HK1072731A1
HK1072731A1 HK05106424.8A HK05106424A HK1072731A1 HK 1072731 A1 HK1072731 A1 HK 1072731A1 HK 05106424 A HK05106424 A HK 05106424A HK 1072731 A1 HK1072731 A1 HK 1072731A1
Authority
HK
Hong Kong
Prior art keywords
composition
antiviral activity
piperazine derivatives
azaindoleoxoacetic piperazine
substituted azaindoleoxoacetic
Prior art date
Application number
HK05106424.8A
Other languages
English (en)
Inventor
Nicholas A Meanwell
John F Kadow
Tao Wang
Zhongxing Zhang
Qiufen May Xue
Zhiwei Yin
Alicia Regueiro-Ren
John D Matiskella
Yasutsugu Ueda
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31714265&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1072731(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of HK1072731A1 publication Critical patent/HK1072731A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
HK05106424.8A 2002-08-07 2005-07-27 Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives HK1072731A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/214,982 US20030207910A1 (en) 2001-02-02 2002-08-07 Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
PCT/US2003/024415 WO2004014380A1 (en) 2002-08-07 2003-08-05 Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives

Publications (1)

Publication Number Publication Date
HK1072731A1 true HK1072731A1 (en) 2005-09-09

Family

ID=31714265

Family Applications (4)

Application Number Title Priority Date Filing Date
HK05106424.8A HK1072731A1 (en) 2002-08-07 2005-07-27 Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
HK13101431.0A HK1174037A1 (en) 2002-08-07 2005-07-27 Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
HK15102916.0A HK1202530A1 (en) 2002-08-07 2015-03-23 Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
HK16108137.9A HK1220181A1 (zh) 2002-08-07 2016-07-12 取代的氮雜吲哚氧代乙酸哌嗪衍生物的組合物及抗病毒作用

Family Applications After (3)

Application Number Title Priority Date Filing Date
HK13101431.0A HK1174037A1 (en) 2002-08-07 2005-07-27 Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
HK15102916.0A HK1202530A1 (en) 2002-08-07 2015-03-23 Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
HK16108137.9A HK1220181A1 (zh) 2002-08-07 2016-07-12 取代的氮雜吲哚氧代乙酸哌嗪衍生物的組合物及抗病毒作用

Country Status (31)

Country Link
US (1) US20030207910A1 (pt)
EP (4) EP1549313B9 (pt)
KR (1) KR101045154B1 (pt)
CN (2) CN100379421C (pt)
AR (1) AR041190A1 (pt)
AU (2) AU2003261367B2 (pt)
BR (1) BRPI0313286B8 (pt)
CA (1) CA2494832C (pt)
CY (3) CY1113413T1 (pt)
DK (3) DK2801576T3 (pt)
ES (4) ES2560844T3 (pt)
GE (1) GEP20084284B (pt)
HK (4) HK1072731A1 (pt)
HR (1) HRP20050123B8 (pt)
HU (1) HUE027396T2 (pt)
IL (1) IL166512A (pt)
IS (1) IS2919B (pt)
MX (1) MXPA05001441A (pt)
MY (1) MY146549A (pt)
NO (1) NO331591B1 (pt)
NZ (1) NZ537930A (pt)
PE (1) PE20040772A1 (pt)
PL (1) PL219566B1 (pt)
PT (3) PT1549313E (pt)
RS (1) RS53428B (pt)
RU (1) RU2325389C2 (pt)
SI (3) SI2801576T1 (pt)
TW (1) TWI328452B (pt)
UA (1) UA82199C2 (pt)
WO (1) WO2004014380A1 (pt)
ZA (1) ZA200501018B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0307834D0 (en) * 2003-04-04 2003-05-14 Ta Contrast Ab Composition
US20050075364A1 (en) * 2003-07-01 2005-04-07 Kap-Sun Yeung Indole, azaindole and related heterocyclic N-substituted piperazine derivatives
US20050124623A1 (en) * 2003-11-26 2005-06-09 Bender John A. Diazaindole-dicarbonyl-piperazinyl antiviral agents
US7745625B2 (en) * 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US7776863B2 (en) * 2004-03-24 2010-08-17 Bristol-Myers Squibb Company Methods of treating HIV infection
US20050215544A1 (en) * 2004-03-24 2005-09-29 Pin-Fang Lin Methods of treating HIV infection
RU2006147278A (ru) 2004-06-09 2008-07-20 Глэксо Груп Лимитед (GB) Производные пирролопиридина
US20060100432A1 (en) * 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US20060100209A1 (en) * 2004-11-09 2006-05-11 Chong-Hui Gu Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US7183284B2 (en) * 2004-12-29 2007-02-27 Bristol-Myers Squibb Company Aminium salts of 1,2,3-triazoles as prodrugs of drugs including antiviral agents
US7601715B2 (en) 2005-06-22 2009-10-13 Bristol-Myers Squibb Company Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein
US7598380B2 (en) * 2005-08-03 2009-10-06 Bristol-Myers Squibb Company Method of preparation of azaindole derivatives
US7851476B2 (en) * 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7807671B2 (en) 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
US7504399B2 (en) * 2006-06-08 2009-03-17 Bristol-Meyers Squibb Company Piperazine enamines as antiviral agents
WO2008005910A2 (en) * 2006-07-06 2008-01-10 Bristol-Myers Squibb Company Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
CA2738429C (en) 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
GB0910667D0 (en) * 2009-06-19 2009-08-05 Glaxo Wellcome Mfg Pte Ltd Novel compounds
EP2601174B1 (en) * 2010-08-06 2014-11-26 Bristol-Myers Squibb Company Substituted indole and azaindole oxoacetyl piperazinamide derivatives
ES2585396T3 (es) * 2010-12-02 2016-10-05 VIIV Healthcare UK (No.5) Limited Alquilamidas como inhibidores de la unión del VIH
CN102718692B (zh) * 2012-07-03 2014-01-08 苏州和健医药科技有限公司 一种7位甲基-5位氧取代吲哚化合物的制备方法
US9580416B2 (en) 2014-07-02 2017-02-28 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
US9758517B2 (en) * 2014-09-17 2017-09-12 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
EP3291813A4 (en) 2015-05-06 2019-01-02 The Regents of The University of California K-ras modulators
US20240293400A1 (en) * 2021-05-21 2024-09-05 Centre National De La Recherche Scientifique Novel azaindole derivatives as antiviral agents

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2761201A (en) 1952-05-02 1956-09-04 Griffin Wheel Co Renewing molds
US3830602A (en) 1973-03-14 1974-08-20 Commercial Shearing Rotary pumps and motors
US5023265A (en) * 1990-06-01 1991-06-11 Schering Corporation Substituted 1-H-pyrrolopyridine-3-carboxamides
IL99843A0 (en) 1990-11-01 1992-08-18 Merck & Co Inc Synergistic combination of hiv reverse transcriptase inhibitors
US5811432A (en) 1990-11-09 1998-09-22 Pfizer Inc Azaoxindole derivatives
ES2097341T3 (es) 1991-07-03 1997-04-01 Upjohn Co Indoles sustituidos como farmacos para el tratamiento del sida.
US5124327A (en) * 1991-09-06 1992-06-23 Merck & Co., Inc. HIV reverse transcriptase
WO1993005020A1 (en) 1991-09-06 1993-03-18 Merck & Co., Inc. Indoles as inhibitors of hiv reverse transcriptase
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
IT1265057B1 (it) 1993-08-05 1996-10-28 Dompe Spa Tropil 7-azaindolil-3-carbossiamidi
US5424329A (en) * 1993-08-18 1995-06-13 Warner-Lambert Company Indole-2-carboxamides as inhibitors of cell adhesion
GB9420521D0 (en) 1994-10-12 1994-11-30 Smithkline Beecham Plc Novel compounds
ATE376547T1 (de) 1999-05-21 2007-11-15 Scios Inc Derivate des indol-typs als p38 kinase inhibitoren
US6469006B1 (en) 1999-06-15 2002-10-22 Bristol-Myers Squibb Company Antiviral indoleoxoacetyl piperazine derivatives
US6476034B2 (en) 2000-02-22 2002-11-05 Bristol-Myers Squibb Company Antiviral azaindole derivatives
US20020061892A1 (en) * 2000-02-22 2002-05-23 Tao Wang Antiviral azaindole derivatives
AU2001268727B2 (en) 2000-07-10 2005-03-24 Viiv Healthcare Uk (No. 5) Limited Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives
US6403211B1 (en) 2000-07-18 2002-06-11 3M Innovative Properties Company Liquid crystal polymer for flexible circuits
IL157029A0 (en) * 2001-02-02 2004-02-08 Bristol Myers Squibb Co Azaindoleoxoacetic piperazine derivatives and pharmaceutical compositions containing the same
EP1476163A4 (en) * 2002-02-23 2009-05-27 Bristol Myers Squibb Co METHOD FOR TREATING HIV INFECTION BY PREVENTING INTERACTION OF CD4 AND GP120

Also Published As

Publication number Publication date
KR20060021811A (ko) 2006-03-08
WO2004014380A1 (en) 2004-02-19
HK1220181A1 (zh) 2017-04-28
MY146549A (en) 2012-08-15
HUE027396T2 (en) 2016-09-28
CY1117217T1 (el) 2017-04-05
PT2497770E (pt) 2014-07-18
DK2497770T3 (da) 2014-07-28
UA82199C2 (uk) 2008-03-25
NZ537930A (en) 2008-01-31
EP2801576A1 (en) 2014-11-12
BRPI0313286A2 (pt) 2005-07-05
EP1549313A1 (en) 2005-07-06
EP1549313B1 (en) 2012-06-27
BRPI0313286B8 (pt) 2021-05-25
ES2641893T3 (es) 2017-11-14
US20030207910A1 (en) 2003-11-06
RU2005106350A (ru) 2005-11-20
MXPA05001441A (es) 2005-06-06
CY1113413T1 (el) 2016-06-22
IS7682A (is) 2005-02-01
IL166512A0 (en) 2006-01-15
AU2009202361B2 (en) 2011-10-13
ES2388919T3 (es) 2012-10-19
DK2801576T3 (en) 2016-03-07
EP2497770A1 (en) 2012-09-12
HRP20050123A2 (en) 2006-02-28
CA2494832C (en) 2012-07-10
EP1549313A4 (en) 2010-08-04
HRP20050123B1 (hr) 2014-04-25
IL166512A (en) 2014-12-31
JP2006504669A (ja) 2006-02-09
EP1549313B9 (en) 2012-11-21
CA2494832A1 (en) 2004-02-19
AR041190A1 (es) 2005-05-04
PT1549313E (pt) 2012-09-05
PL219566B1 (pl) 2015-05-29
EP2497770B1 (en) 2014-05-14
GEP20084284B (en) 2008-01-10
CN100379421C (zh) 2008-04-09
ES2560844T3 (es) 2016-02-23
EP2801576B1 (en) 2015-12-09
TWI328452B (en) 2010-08-11
JP4430539B2 (ja) 2010-03-10
BRPI0313286A8 (pt) 2018-05-08
PT2801576E (pt) 2016-03-03
BRPI0313286B1 (pt) 2019-02-05
CN1688311A (zh) 2005-10-26
RS53428B (en) 2014-12-31
CY1115580T1 (el) 2017-01-04
AU2003261367A1 (en) 2004-02-25
NO331591B1 (no) 2012-01-30
RU2325389C2 (ru) 2008-05-27
TW200410696A (en) 2004-07-01
HK1202530A1 (en) 2015-10-02
NO20050514L (no) 2005-03-18
PL375360A1 (en) 2005-11-28
HK1174037A1 (en) 2013-05-31
KR101045154B1 (ko) 2011-07-04
SI1549313T1 (sl) 2013-01-31
EP2975038A1 (en) 2016-01-20
SI2801576T1 (sl) 2016-03-31
DK1549313T3 (da) 2012-10-01
CN101229164B (zh) 2013-01-02
AU2003261367B2 (en) 2009-03-12
HRP20050123B8 (hr) 2015-04-10
IS2919B (is) 2015-01-15
AU2009202361A1 (en) 2009-07-02
CN101229164A (zh) 2008-07-30
EP2975038B1 (en) 2017-07-12
ES2481044T3 (es) 2014-07-29
PE20040772A1 (es) 2004-11-20
ZA200501018B (en) 2006-09-27
RS20050108A (en) 2007-09-21
SI2497770T1 (sl) 2014-11-28

Similar Documents

Publication Publication Date Title
HK1220181A1 (zh) 取代的氮雜吲哚氧代乙酸哌嗪衍生物的組合物及抗病毒作用
TWI318978B (en) Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
PL376566A1 (pl) Pochodne podstawionych 2-alkiloamino-nikotynamidów oraz sposoby wykorzystania
EP1465615A4 (en) TRICYCLIC BISENONE DERIVATIVES AND METHODS OF USE
PL1648874T3 (pl) Pochodne piperazyny i ich zastosowanie jako środków leczniczych
SI1583763T1 (sl) Benzoazolilpiperazinski derivati, ki imajo VR1 antagonistično delovanje
PL376532A1 (pl) Pochodne podstawionych benzyloamin oraz sposoby wykorzystania
HK1061854A1 (en) Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
HK1099014A1 (en) Malonamide derivatives blocking the activity of gama-secretase
PL376575A1 (pl) Podstawione związki heterocykliczne oraz sposoby wykorzystania
HUP0401735A3 (en) Piperazine derivatives with ccr1 receptor antagonist activity and pharmaceutical compositions containing them
AU2003269364A1 (en) Use of piperazine derivatives as ccr1 antagonists
HK1080487A1 (en) Heterocyclic compounds having elastase-inhibiting activity and intermediates thereof
HUP0303364A3 (en) Pyrimidine derivatives of arylalkane-sulfonamides having endothelin-antagonist activity, pharmaceutical compositions containing them and their use
PL372697A1 (en) Phosphonates and derivatives thereof as enhancers of the activity of insecticides
PL378027A1 (pl) Nowe pochodne piperazyny i ich zastosowanie jako związków pośrednich w syntezie
SI1363705T1 (sl) Sestavek in antivirusna aktivnost substituiranih azaindoleoksoocetnih piperazinskih derivatov
EP1559719A4 (en) NEW ANTIMYCOTIC ACTIVITY REINFORCING MAKROLIDE DERIVATIVES
AU2003264474A8 (en) Novel uracil derivatives and medicinal use thereof
HK1073243A1 (en) Use of N-(indolecarbonyl-) piperazine derivatives
AU2003260515A8 (en) Derivatives of 4-4'-bipyridyl-2-2'-bisoxazoles and 4-4'-bipyridyl-2-2'-bistiazoles as antineoplasic agents
HUP0203929D0 (en) New use of substituted alkyl-piridazinone derivatives
ZA200500735B (en) Novel quinuclidine derivatives and their use
PL360228A1 (en) Application of carborates and metalcarborates and their derivatives

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210813